Screener
Indivior Pharmaceuticals, Inc. INDV Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities, current | 9 | 10 |
| Income taxes payable | 26 | 2 |
| Total current liabilities | 779 | 914 |
| Long-term debt, less current portion | 486 | 290 |
| Accrued litigation settlement expenses, noncurrent | 41 | 52 |
| Operating lease liabilities, noncurrent | 14 | 22 |
| Other noncurrent liabilities | 21 | 21 |
| Total liabilities | $1,341 | $1,300 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s long-term debt?
- Indivior Pharmaceuticals, Inc. (INDV) reported long-term debt of $486M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s long-term debt increased by 56.3% year-over-year, from $311M to $486M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s long-term debt?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s long-term debt has grown at a 10.6% compound annual growth rate (CAGR), from $237M to $290M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Indivior Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude